Beijing Biostar Pharmaceuticals Co., Ltd. (HKG: 2563)
Hong Kong
· Delayed Price · Currency is HKD
16.16
+0.88 (5.76%)
Jan 3, 2025, 4:08 PM HKT
Beijing Biostar Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Dec '23 Dec 31, 2023 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 66.64 | 66.64 | 32.82 | 71.06 | - | - |
| Revenue Growth (YoY) | - | 103.03% | -53.82% | - | - | - |
| Cost of Revenue | 19.81 | 19.81 | 8.94 | 4.17 | - | - |
| Gross Profit | 46.83 | 46.83 | 23.88 | 66.89 | - | - |
| Selling, General & Admin | 139.3 | 139.3 | 149.41 | 267.37 | 39.35 | 38.79 |
| Research & Development | 126.54 | 126.54 | 82.74 | 91.97 | 35.57 | 31.35 |
| Other Operating Expenses | -1.25 | -1.25 | -15.25 | 0.96 | 0.8 | 0.6 |
| Operating Expenses | 263.3 | 263.3 | 218.11 | 360.69 | 75.67 | 70.77 |
| Operating Income | -216.47 | -216.47 | -194.23 | -293.79 | -75.67 | -70.77 |
| Interest Expense | -0.06 | -0.06 | -0.07 | -0.07 | - | - |
| Interest & Investment Income | 13.14 | 13.14 | 3.34 | 14.11 | 5.67 | 5.75 |
| Currency Exchange Gain (Loss) | 4.65 | 4.65 | 19.6 | -4.9 | -1.79 | - |
| Other Non Operating Income (Expenses) | - | - | - | -0.03 | -0.02 | -0.01 |
| EBT Excluding Unusual Items | -198.74 | -198.74 | -171.36 | -284.68 | -71.8 | -65.03 |
| Gain (Loss) on Sale of Investments | 9.1 | 9.1 | 10.85 | 8.46 | 2.04 | 3.7 |
| Other Unusual Items | - | - | - | -1.92 | 4.51 | 5.41 |
| Pretax Income | -189.64 | -189.64 | -160.51 | -278.14 | -65.25 | -55.92 |
| Net Income | -189.64 | -189.64 | -160.51 | -278.14 | -65.25 | -55.92 |
| Net Income to Common | -189.64 | -189.64 | -160.51 | -278.14 | -65.25 | -55.92 |
| Shares Outstanding (Basic) | 350 | 350 | 350 | 350 | - | - |
| Shares Outstanding (Diluted) | 350 | 350 | 350 | 350 | - | - |
| EPS (Basic) | -0.54 | -0.54 | -0.46 | -0.79 | - | - |
| EPS (Diluted) | -0.54 | -0.54 | -0.46 | -0.79 | - | - |
| Free Cash Flow | -177.17 | -177.17 | -111.3 | -89.83 | -63.95 | -66.68 |
| Free Cash Flow Per Share | -0.51 | -0.51 | -0.32 | -0.26 | - | - |
| Gross Margin | 70.27% | 70.27% | 72.76% | 94.13% | - | - |
| Operating Margin | -324.87% | -324.87% | -591.81% | -413.42% | - | - |
| Profit Margin | -284.60% | -284.60% | -489.06% | -391.40% | - | - |
| Free Cash Flow Margin | -265.88% | -265.88% | -339.12% | -126.41% | - | - |
| EBITDA | -207.3 | -207.3 | -185.14 | -286.11 | -68.61 | -64.09 |
| D&A For EBITDA | 9.17 | 9.17 | 9.1 | 7.69 | 7.06 | 6.67 |
| EBIT | -216.47 | -216.47 | -194.23 | -293.79 | -75.67 | -70.77 |
Source: S&P Capital IQ. Standard template.
Financial Sources.